ID 52698
Sort Key
2
Title Alternative
The 2013 Incentive Award of the Okayama Medical Association in Cancer Research (2013 Hayashibara Prize and Yamada Prize)
FullText URL
Thumnail 126_87.pdf 277 KB
Author
Miyahara, Koji
Note
平成25年度岡山医学会賞紹介記事 (The 2013 Okayama Medical Association Award)
Publication Title
岡山医学会雑誌
Published Date
2014-08-01
Volume
volume126
Issue
issue2
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
87
End Page
88
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
OAI-PMH Set
岡山大学
language
日本語
Copyright Holders
Copyright (c) 2014 岡山医学会
File Version
publisher
Refereed
True
DOI
NAID
Eprints Journal Name
joma
References
1) Kaneko S, Furuse J, Kudo M, Ikeda K, Honda M, Nakamoto Y, Onchi M, Shiota G, Yokosuka O, Sakaida I, Takehara T, Ueno Y, et al. : Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res (2012) 42, 523-542.
2) Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, et al. : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 24, 378-390.
3) Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, et al. : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2009) 10, 25-34.
4) Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, et al. : Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 26, 1604-1611.
5) Laurén J, Gunji Y, Alitalo K : Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol (1998) 153, 1333-1339.
6) Kozian DH, Ziche M, Augustin HG : The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest (1997) 76, 267-276.
7) Zarnegar R : Regulation of HGF and HGFR gene expression. EXS (1995) 74, 33-49.
8) Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR : Biological action of leptin as an angiogenic factor. Science (1998) 281, 1683-1686.
9) Cao G, Fehrenbach ML, Williams JT, Finklestein JM, Zhu JX, Delisser HM : Angiogenesis in platelet endothelial cell adhesion molecule-1-null mice. Am J Pathol (2009) 175, 903-915.
10) Hicklin DJ, Ellis LM : Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2005) 23, 1011-1027.
11) Abramsson A, Lindblom P, Betsholtz C : Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest (2003) 112, 1142-1151.
12) LeCouter J, Lin R, Tejada M, Frantz G, Peale F, Hillan KJ, Ferrara N : The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis : Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A (2003) 100, 2685-2690.